Home >  News >  Industry >  Pharma News >  Pfizer emergency use plea...

Pfizer emergency use plea for Covid-19 Vaccine rejected by SEC Committee

By - Ruchika Sharma
Published On 2021-02-06 06:55 GMT   |   Update On 2021-02-06 06:55 GMT
Advertisement

New Delhi: Just two days before pharma major Pfizer announced withdrawal of its application for emergency use authorisation of its Covid-19 vaccine in India, an expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage, officials said on Friday.

Pfizer on Friday said it has decided to withdraw its application for emergency use authorisation of its Covid-19 vaccine in India.
It was the first pharmaceutical firm to seek such an authorisation from the Drugs Controller General of India (DCGI) on December 5 for its Covid-19 vaccine, after it secured such clearance in the UK and Bahrain.
On February 3, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) deliberated on Pfizer's application.
The firm presented its proposal for emergency use authorisation of Covid-19 mRNA Vaccine BNT162b before the committee, an official said.
Advertisement
"The committee noted that incidents of palsy, anaphylaxis and other SAE's have been reported during post marketing and the causality of the events with the vaccine is being investigated.
"Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population. After detailed deliberation, the committee has not recommended for grant of permission for emergency use in the country at this stage," the recommendations of the SEC stated.
As of now, two vaccines -- Covishield, manufactured by Serum Institute of India, and Bharat Biotech's Covaxin -- have been approved for restricted emergency use in India.
A Pfizer company spokesperson in a statement said that in pursuance of the emergency use authorisation of its Covid-19 vaccine, the firm participated in the SEC meeting.
"Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," the spokesperson said.
Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future, the statement said.
"Pfizer remains committed to making its vaccine available for use by the government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," the spokesperson said.
Pfizer in its application submitted to the drug regulator in December 2020, had sought permission to import the vaccine for sale and distribution in India, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, according to official sources.

Read also: Pfizer to continue seeking Covid-19 vaccine approval in India, if Govt makes purchase commitment: Report



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Agitated Over Late Medicine Delivery, Man Fires Air Gun, Booked for Attempt to Murder

Sun Pharma, Alembic Pharma and 1 other recall products in US

Sun Pharma's Dapagliflozin, Glimepiride, Metformin FDC Fails to Secure CDSCO Panel Nod Over Safety, Utility Concerns

Submit BE Raw Data, Interaction Study on Dapagliflozin-Rosuvastatin FDC: Expert Panel Tells Pure and Cure

Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan for previously treated Advanced EGFR Mutated Non Small Cell Lung Cancer

Alembic Pharma wins USFDA approval for pulmonary arterial hypertension drug Macitentan

Merck, Daiichi Sankyo Ifinatamab deruxtecan granted Breakthrough Therapy Designation by USFDA for pretreated extensive-stage small cell lung cancer

Boehringer Ingelheim, Palatin Technologies to develop melanocortin receptor targeted treatment for retinal diseases